Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. William J. McKenna
The classification of the cardiomyopathies focuses on clinical phenotyping to establish a diagnosis, with acquisition of a 2 to 3 generation pedigree and, when appropriate/feasible, mutation analysis to identify the specific disease subtype.
Diagnosis relies on a detailed history, electrocardiography and imaging. The diagnostic criteria and molecular genetic basis for HCM, DCM, and ARVC are well established. However, when there are associated phenotypes (e.g. HCM with pre-excitation, DCM with conduction disease) or unusual features (e.g. low voltage ECG, multi-organ involvement), then other diagnoses (e.g. storage disease, lamin A/C disease, amyloidosis, mitochondrial disease) should be considered. Though not universally readily available, CMR and mutation analysis may contribute to diagnoses in specific instances, though the prognostic significance of both remains to be established. Endomyocardial biopsy is important in the assessment of unexplained cardiac dysfunction to enable a diagnosis and, in particular, to identify treatable conditions which may otherwise be lethal (e.g. giant cell myocarditis, sarcoidosis).
Session Title: Cardiomyopathies: diagnostic clues not to be missed
© 2017 European Society of Cardiology. All rights reserved